Prognostic impact of tumor lymphocytic infiltrates in patients with breast cancer undergoing neoadjuvant chemotherapy

dc.contributor.authorAvci, Nilufer
dc.contributor.authorDeligonul, Adem
dc.contributor.authorTolunay, Sahsine
dc.contributor.authorCubukcu, Erdem
dc.contributor.authorOlmez, Omer Fatih
dc.contributor.authorAltmisdortoglu, Ozgur
dc.contributor.authorEvrensel, Turkkan
dc.date.accessioned2026-08-12T16:40:24Z
dc.date.issued2015
dc.departmentFırat Üniversitesi
dc.description.abstractPurpose: The presence of a pronounced tumor lymphocytic infiltrate (TLI) is deemed to reflect the presence of an immunoinflammatory response against the tumor and may thus have prognostic significance. We investigated the prognostic value of TLI detected in pathological specimens collected following neoadjuvant chemotherapy (NACT) in patients with breast cancer. Methods: 100 consecutive patients with breast cancer (mean age 47.8 +/- 11.4 years) who were scheduled to undergo anthracycline- and/or taxane-containing NACT were enrolled. Specimens collected after NACT were scored with the 4-point Klintrup scoring criteria for the presence of TLI. Results: 60 patients had low-grade TLI and 40 high-grade TLI. Comparison of the patient population according to low-grade vs high-grade TLI revealed statistically significant difference both in terms of disease-free survival (DFS) (log rank=4.28, p<0.05) and overall survival (OS) (log rank=3.96, p<0.05), with high-grade TLI patients showing a better prognosis. Multivariate Cox regression analysis identified postoperative tumor size and low-grade TLI as the two main independent adverse prognostic factors. Conclusion: High-grade TLI may interfer with tumor growth and can represent a favorable prognostic factor in women with breast cancer undergoing NACT.
dc.identifier.endpage1000
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue4
dc.identifier.orcid0009-0000-6166-4466
dc.identifier.orcid0000-0002-5609-9658
dc.identifier.orcid0000-0002-0598-7284
dc.identifier.pmid26416041
dc.identifier.scopus2-s2.0-84943275300
dc.identifier.scopusqualityN/A
dc.identifier.startpage994
dc.identifier.urihttps://hdl.handle.net/11508/45393
dc.identifier.volume20
dc.identifier.wosWOS:000361421900007
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherImprimatur Publications
dc.relation.ispartofJournal of Buon
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectbreast cancer
dc.subjectneoadjuvant chemotherapy
dc.subjectprognosis
dc.subjecttumor lymphocytic infiltrates
dc.titlePrognostic impact of tumor lymphocytic infiltrates in patients with breast cancer undergoing neoadjuvant chemotherapy
dc.typeArticle

Dosyalar